

Drug resistance interpretation: PRHIVDB 9.5.1 (2023-11-05)

PI Major Mutations:None

PI Accessory Mutations:**L33F**^{99%}_{seen:27,918}

PR Other Mutations:**I13V**^{100%}_{seen:35,008} • **M36I**^{100%}_{seen:38,952} • **P39S**^{99%}_{seen:26,852} • **R41K**^{99%}_{seen:25,333} • **R57K**^{99%}_{seen:23,882} • **E65D**^{99%}_{seen:22,375} • **H69K**^{99%}_{seen:22,763} • **L89M**^{100%}_{seen:20,875}

Protease Inhibitors

atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Potential Low-Level Resistance
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Potential Low-Level Resistance
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Potential Low-Level Resistance

PR comments

Accessory

- L33F** is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to LPV, ATV, and DRV.

Mutation scoring: PRHIVDB 9.5.1 (2023-11-05)

Drug resistance mutation scores of PI:

Download CSV

Rule	ATV/r	DRV/r	FPV/r	IDV/r	LPV/r	NFV	SQV/r	TPV/r
L33F	5	5	10	5	5	10	5	10

Drug resistance interpretation: RTHIVDB 9.5.1 (2023-11-05)

NRTI Mutations:None

NNRTI Mutations:None

RT Other Mutations:**V35T**^{100%}_{seen:15,114} • **T39A**^{99%}_{seen:925} • **S519N**^{99%}_{seen:1,367} • **Q524K**^{99%}_{seen:2,297} • **K527AE**^{100%, 1, 11%}_{seen:2,258} • **E529D**^{100%}_{seen:2,862} • **A534S**^{100%}_{seen:1,887} • **A554S**^{100%}_{seen:1,080} • **V559I**^{100%}_{seen:1,088}

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	Susceptible
stavudine (D4T)	Susceptible	etravirine (ETR)	Susceptible
didanosine (DDI)	Susceptible	nevirapine (NVP)	Susceptible
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		

Mutation scoring: RTHIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: INHIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations:None

INSTI Accessory Mutations:None

IN Other Mutations:**D6DA**^{0, 82%, 1, 17%}_{seen:1,176} • **K7R**^{100%}_{seen:1,082} • **K14KR**^{0, 10%, 0, 49%}_{seen:1,111} • **V31I**^{100%}_{seen:1,783} • **I60M**^{100%}_{seen:2,111} • **I72V**^{100%}_{seen:2,267} • **T112LV**^{0, 88%, 1, 12%}_{seen:2,883} • **I113V**^{100%}_{seen:2,883} • **T124A**^{99%}_{seen:2,279} • **T125A**^{100%}_{seen:2,279} • **V126F**^{100%}_{seen:2,279} • **G134N**^{99%}_{seen:1,112} • **I135V**^{0, 95%, 1, 10%}_{seen:2,172} • **K136Q**^{99%}_{seen:2,112} • **D167E**^{100%}_{seen:12,670} • **K173R**^{100%}_{seen:15,753} • **V201I**^{99%}_{seen:1,292} • **T218I**^{100%}_{seen:1,288} • **L234I**^{100%}_{seen:1,349} • **S283G**^{100%}_{seen:4,114}

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

Mutation scoring: INHIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for INSTI.